Isis Reports Interim Data From Phase 2 Study Of ISIS-APOCIIIRx - Quick Facts

(RTTNews) - Isis Pharmaceuticals, Inc. (ISIS) announced interim data from an ongoing Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with very high to severely high triglycerides.

In this study, patients treated with ISIS-APOCIIIRx achieved statistically significant mean reductions of up to 79 percent in apolipoprotein C-III (apoC-III) and up to 75 percent in triglycerides.

In addition, patients treated with ISIS-APOCIIIRx achieved statistically significant mean increases of up to 57 percent in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol. Patients also achieved up to 89 percent mean reduction in apoC-III-associated very low-density lipoprotein (VLDL) particles.

The company also announced that it looks forward to discussing its Phase 3 plans with regulators and moving rapidly into a Phase 3 program next year in patients with severely high triglycerides.